Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency-Reference-Cited by-同舟云学术

Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency

Published:2012-12 Issue:16 Volume:13 Page:1961-1965
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Autmizguine Julie¹²,Krajinovic Maja²³⁴⁵,Rousseau Julie⁴,Théorêt Yves³⁴⁵,Litalien Catherine²³⁴⁵,Marquis Christopher⁶,Tapiéro Bruce¹²⁴,Ovetchkine Philippe⁷

Affiliation:

1. Infectious Diseases Division, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada

2. Department of Pediatrics, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada

3. Clinical Pharmacology Unit, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada

4. Research Center, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada

5. Department of Pharmacology, University of Montreal, Montreal (QC), Canada

6. Department of Pharmacy, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada

7. Infectious Diseases Division, CHU Sainte-Justine – University of Montreal, Montreal (QC), Canada.

Abstract

We report the case of a patient highly susceptible to invasive aspergillosis who received treatment with voriconazole (VRC). As part of therapeutic drug monitoring, VRC plasma trough concentrations were measured, showing undetectable levels (<0.16 µg/ml). Genotyping showed a heterozygous profile CYP2C19*1/*17, known to be associated with an ultrarapid-metabolism phenotype, contributing to the very low systemic exposure observed. Therefore, in this situation, the use of VRC treatment could be associated with therapeutic failure.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs.12.175

Reference20 articles.

1. Itraconazole to Prevent Fungal Infections in Chronic Granulomatous Disease

2. Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America

3. Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes

4. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics*

5. Voriconazole Therapeutic Drug Monitoring

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PharmGKB summary;Pharmacogenetics and Genomics;2017-05

2. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014;Internal Medicine Journal;2014-12